QUIDE
LOE Approachingpiperacetazine
NDAORALTABLET
Approved
Feb 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUIDE (piperacetazine) is an oral antipsychotic tablet approved in 1969 for the treatment of psychotic disorders. As a phenothiazine derivative, it works by blocking dopamine receptors in the central nervous system. The drug represents an older generation of antipsychotic therapy with established clinical utility in schizophrenia and related conditions.
LOE Approaching
This mature legacy product approaching loss of exclusivity is unlikely to support large commercial teams or significant growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QUIDE represents a legacy maintenance product with minimal career growth opportunity; roles are typically focused on compliance, supply chain continuity, and managing a declining market presence. Career trajectories on this product are unlikely to accelerate professional development or visibility within modern pharma organizations.
Brand Manager (legacy)Field Sales
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.